Effects of Beta Adrenergic Receptor Agonists and Antagonists in Diabetics with Symptoms of Postural Hypotension: A Double-Blind, Placebo-Controlled Study

Cleophas, Ton J. M.; Kauw, Frans H. W.; Bijl, Cees; Meijers, Jacques; Stapper, Gerard
November 1986
Angiology;Nov1986, Vol. 37 Issue 11, p855
Academic Journal
Eleven patients with hyperadrenergic diabetic postural hypotension and vagal neuropathy were treated in a double-blind, placebo-controlled study with different beta-agonists and antagonists. A single dose of the beta2-agonist terbutaline (5 mg) and the beta1+2-agonist orciprenaline (10 mg) did not reduce the fall in systolic pressure on standing up, despite a significant increase in both supine and standing heart rates. The beta1-antagonist with intrinsic sympathicomimetic activity (ISA) acebutolol (200 mg) and the beta1-antagonist metoprolol (50 mg) did not influence the fall in systolic pressure either, despite a significant decrease in supine and standing heart rates and disappearance of increase in heart rate on standing up. Only the beta1+2-antagonist propranolol and the beta1+2-antagonist with ISA pindolol (5 mg) could significantly reduce or practically abolish the fall in systolic and diastolic pressure on standing up. This was accompanied by a slight decrease of heart rates and disappearance of difference between supine and standing heart rates, as seen with the other beta-antagonists. Thus, only beta2-blockade reduced or abolished the fall in systolic pressure on standing up in our patients. These data were confirmed by a three-week crossover trial in 10 of these patients.


Related Articles

  • β-adrenoceptor agonists increase cardiovascular risk.  // Reactions Weekly;8/21/2004, Issue 1015, p5 

    Discusses research being done on cardiovascular effects of beta-agonists on patients with asthma. Reference to a study by S. R. Salpeter et al., published in the June 2004 issue of the journal "Chest"; Background on an increase in the risk of the disease; Comparison to the effectiveness of placebo.

  • Review: Regular inhaled short-acting β[sub2]-agonists improve lung function in stable chronic obstructive pulmonary disease.  // ACP Journal Club;Jan/Feb2004, Vol. 140 Issue 1, p12 

    This article focuses on a study regarding regular inhaled short acting β[sub2] agonists (ISABAs) for the management of stable chronic obstructive pulmonary disease (COPD), published in the 2003 issue of the journal "Thorax." For this study the researchers selected studies if they were...

  • Long-acting beta2-agonists in asthma: not so SMART? Currie, Graeme P.; Lee, Daniel K. C.; Lipworth, Brian J. // Drug Safety;2006, Vol. 29 Issue 8, p647 

    Asthma is a worldwide chronic disorder that is characterised by airway inflammation and hyper-responsiveness, which results in intermittent airflow obstruction and subsequent perception of symptoms and exacerbations. Inhaled corticosteroids are a fundamental component in the prevention of the...

  • Steroid or Steroid Plus Long-Acting Beta Agonist for Mild Persistent Asthma.  // Neurology Alert;May2011 Supplement, p1 

    The article discusses results of a study which showed that inhaled corticosteroids (ICS)/long-acting beta agonist (LABA) is superior to placebo than ciclesonide (CIC) in asthma control, referencing the report "Comparison of the effect of low-dose ciclesonide and fixed-dose fluticasone propionate...

  • Detection and Confirmation of Ractopamine and Its Metabolites in Horse Urine After Paylean® Administration. Lehner, A.F.; Hughes, C.G.; Harkins, J.D.; Nickerson, C.; Mollett, B.; Dirikolu, L.; Bosken, J.; Camargo, F.; Boyles, J.; Troppmann, A.; Karpiesiuk, W.; Woods, W.E.; Tobin, T. // Journal of Analytical Toxicology;May/Jun2004, Vol. 28 Issue 4, p226 

    Investigates the detection, confirmation and metabolism of beta-adrenergic agonist ractopamine administered as Paylean to the horse. Instrumental limit of detection derived from the experiment; Ractopamine equivalents detected in unhydrolyzed urine; Methods that provide an effective pathway for...

  • 2008 - Review: Long-acting beta-agonists do not increase risk for asthma-related hospitalization in patients taking inhaled corticosteroids. Shafazand, Shirin // ACP Journal Club;3/17/2009, Vol. 150 Issue 3, p3 

    The article deliberates on the safety of using concomitant therapy with long-acting beta-agonists (LABAs) in asthma patients who are taking inhaled corticosteroids (ICSs). Research conducted reveals that asthma patients who are taking ICSs, concomitant therapy with long-acting beta-agonists does...

  • Long-acting beta-agonists: More dangerous than we thought? Aschgoodkin, Judith; Kaplan, Deborah // Patient Care;Aug2006, Vol. 40 Issue 8, p13 

    The article discusses research on the role of long-acting beta-agonists (LABA) in the management of asthma. According to research, LABAs may increase severe and life-threatening asthma exacerbations, hospitalizations, intensive care unit admissions, and asthma-related deaths. The factors that...

  • ritodrine hydrochloride.  // Royal Society of Medicine: Medicines;2002, p478 

    The article presents information on ritodrine hydrochloride, a sympathomimetic and beta-receptor stimulant drug which can be used in obstetrics to prevent or delay premature labour by relaxing the uterus. Administration is either oral or by injection. Side effects include muscle tremor, nausea,...

  • Why β-blockers are vital cardiovascular tools. Minhas, Rubin // Pulse;11/1/2004, Vol. 64 Issue 43, p44 

    Focuses on the role of β-blockers in cardiovascular disease medication. Efficacy in cardiovascular disease treatment; Effects of different classes of β-blockers; Adverse effects and contradictions; Considerations for clinical use. INSETS: The shifting ground on β-blockers;2 Summary of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics